832 related articles for article (PubMed ID: 18396126)
1. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement.
Endo I; Fukumoto S; Ozono K; Namba N; Tanaka H; Inoue D; Minagawa M; Sugimoto T; Yamauchi M; Michigami T; Matsumoto T
Bone; 2008 Jun; 42(6):1235-9. PubMed ID: 18396126
[TBL] [Abstract][Full Text] [Related]
2. Serum FGF23 levels in normal and disordered phosphorus homeostasis.
Weber TJ; Liu S; Indridason OS; Quarles LD
J Bone Miner Res; 2003 Jul; 18(7):1227-34. PubMed ID: 12854832
[TBL] [Abstract][Full Text] [Related]
3. Levels and dynamic changes of serum fibroblast growth factor 23 in hypophosphatemic rickets/osteomalacia.
Xia WB; Jiang Y; Li M; Xing XP; Wang O; Hu YY; Zhang HB; Liu HC; Meng XW; Zhou XY
Chin Med J (Engl); 2010 May; 123(9):1158-62. PubMed ID: 20529556
[TBL] [Abstract][Full Text] [Related]
4. FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets.
Imel EA; Hui SL; Econs MJ
J Bone Miner Res; 2007 Apr; 22(4):520-6. PubMed ID: 17227222
[TBL] [Abstract][Full Text] [Related]
5. Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment.
Endo I; Fukumoto S; Ozono K; Namba N; Inoue D; Okazaki R; Yamauchi M; Sugimoto T; Minagawa M; Michigami T; Nagai M; Matsumoto T
Endocr J; 2015; 62(9):811-6. PubMed ID: 26135520
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia.
Aono Y; Yamazaki Y; Yasutake J; Kawata T; Hasegawa H; Urakawa I; Fujita T; Wada M; Yamashita T; Fukumoto S; Shimada T
J Bone Miner Res; 2009 Nov; 24(11):1879-88. PubMed ID: 19419316
[TBL] [Abstract][Full Text] [Related]
7. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia.
Shimizu Y; Tada Y; Yamauchi M; Okamoto T; Suzuki H; Ito N; Fukumoto S; Sugimoto T; Fujita T
Bone; 2009 Oct; 45(4):814-6. PubMed ID: 19555782
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor 23 and its receptors.
Yu X; White KE
Ther Apher Dial; 2005 Aug; 9(4):308-12. PubMed ID: 16076372
[TBL] [Abstract][Full Text] [Related]
9. Regulation of phosphate homeostasis in infants, children, and adolescents, and the role of phosphatonins in this process.
Garabedian M
Curr Opin Pediatr; 2007 Aug; 19(4):488-91. PubMed ID: 17630616
[TBL] [Abstract][Full Text] [Related]
10. Three novel mutations of the PHEX gene in three Chinese families with X-linked dominant hypophosphatemic rickets.
Xia W; Meng X; Jiang Y; Li M; Xing X; Pang L; Wang O; Pei Y; Yu LY; Sun Y; Hu Y; Zhou X
Calcif Tissue Int; 2007 Dec; 81(6):415-20. PubMed ID: 18046499
[TBL] [Abstract][Full Text] [Related]
11. [Chronic bone pain due to raised FGF23 production? The importance of determining phosphate levels].
de Jongh RT; Vervloet MG; Bravenboer N; Heijboer AC; den Heijer M; Lips P
Ned Tijdschr Geneeskd; 2013; 157(28):A5908. PubMed ID: 23841927
[TBL] [Abstract][Full Text] [Related]
12. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization.
Quarles LD
Am J Physiol Endocrinol Metab; 2003 Jul; 285(1):E1-9. PubMed ID: 12791601
[TBL] [Abstract][Full Text] [Related]
13. FGF23 and disorders of phosphate homeostasis.
Yu X; White KE
Cytokine Growth Factor Rev; 2005 Apr; 16(2):221-32. PubMed ID: 15863037
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.
Jonsson KB; Zahradnik R; Larsson T; White KE; Sugimoto T; Imanishi Y; Yamamoto T; Hampson G; Koshiyama H; Ljunggren O; Oba K; Yang IM; Miyauchi A; Econs MJ; Lavigne J; Jüppner H
N Engl J Med; 2003 Apr; 348(17):1656-63. PubMed ID: 12711740
[TBL] [Abstract][Full Text] [Related]
15. X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment.
Kinoshita Y; Fukumoto S
Endocr Rev; 2018 Jun; 39(3):274-291. PubMed ID: 29381780
[TBL] [Abstract][Full Text] [Related]
16. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia.
Shimada T; Mizutani S; Muto T; Yoneya T; Hino R; Takeda S; Takeuchi Y; Fujita T; Fukumoto S; Yamashita T
Proc Natl Acad Sci U S A; 2001 May; 98(11):6500-5. PubMed ID: 11344269
[TBL] [Abstract][Full Text] [Related]
17. Elevated serum FGF23 concentrations in plasma cell dyscrasias.
Stewart I; Roddie C; Gill A; Clarkson A; Mirams M; Coyle L; Ward C; Clifton-Bligh P; Robinson BG; Mason RS; Clifton-Bligh RJ
Bone; 2006 Aug; 39(2):369-76. PubMed ID: 16644301
[TBL] [Abstract][Full Text] [Related]
18. Clinical performance of a novel chemiluminescent enzyme immunoassay for FGF23.
Ito N; Kubota T; Kitanaka S; Fujiwara I; Adachi M; Takeuchi Y; Yamagami H; Kimura T; Shinoda T; Minagawa M; Okazaki R; Ozono K; Seino Y; Fukumoto S
J Bone Miner Metab; 2021 Nov; 39(6):1066-1075. PubMed ID: 34255195
[TBL] [Abstract][Full Text] [Related]
19. Tumor-induced osteomalacia associated with a maxillofacial tumor producing fibroblast growth factor 23: report of a case and review of the literature.
Mori Y; Ogasawara T; Motoi T; Shimizu Y; Chikazu D; Tamura K; Fukumoto S; Takato T
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Mar; 109(3):e57-63. PubMed ID: 20219587
[TBL] [Abstract][Full Text] [Related]
20. Intact Fibroblast Growth Factor 23 Concentrations in Hypophosphatemic Disorders.
Ramos P; Larson B; Ashrafzadeh-Kian S; Ito N; Kato H; Bornhorst JA; Algeciras-Schimnich A
Endocr Pract; 2023 Mar; 29(3):193-198. PubMed ID: 36627024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]